Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study
Latest Information Update: 19 Dec 2024
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary) ; Firmonertinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms Better Brain
- 19 Dec 2024 New trial record